Indium (111In) igovomab

Short description: Chemical compound

Indium (111In) igovomabMonoclonal antibody

Type| F(ab')2 fragment
Source| Mouse
Target| CA-125
Clinical data
ATC code|

* none

Identifiers
CAS Number|

* 171656-50-1 N

ChemSpider|

* none

UNII|

* GBK36SFC9C

NY (what is this?) (verify)

Indium (111In) igovomab (trade name Indimacis-125) was a mouse monoclonal antibody for the diagnosis of ovarian cancer.[citation needed]

Linked to the chelating agent DTPA and labelled with Indium-111, it was used for imaging (radio-immuno scintigraphy) of the cancer.[citation needed] The drug is no longer available.[1][2]

## References

1. ↑ Google books: Handbook of Therapeutic Antibodies, vol. 3
2. ↑ Biopharma: indium (111 In) igovomab - Indimacis 125[yes|permanent dead link|dead link}}]

* v
* t
* e

Monoclonal antibodies for tumors

Tumor
("-t(u[m])-")|

| Human ("-tumu-")|

* Adecatumumab§
* Ascrinvacumab§
* Cixutumumab§
* Conatumumab§
* Daratumumab
* Drozitumab§
* Duligotumab§
* Dusigitumab§
* Enfortumab vedotin†
* Enoticumab§
* Figitumumab§
* Ganitumab†
* Glembatumumab vedotin†
* Intetumumab§
* Ipilimumab
* Iratumumab§
* Istiratumab
* Icrucumab§
* Lexatumumab§
* Lucatumumab§
* Mapatumumab§
* Narnatumab§
* Necitumumab
* Nesvacumab§
* Nivolumab
* Ofatumumab
* Olaratumab†
* Panitumumab
* Patritumab§
* Pembrolizumab
* Pritumumab§
* Radretumab§
* Ramucirumab
* Rilotumumab†
* Robatumumab§
* Seribantumab§
* Tarextumab§
* Teprotumumab†
* Tovetumab§
* Vantictumab§
* Votumumab§
* Zalutumumab†

"-melu-" (melanoma)
Flanvotumab§

|

Mouse ("-tumo-")|

* Altumomab pentetate
* Anatumomab mafenatox
* Arcitumomab
* Bectumomab
* Blinatumomab
* Detumomab
* Ibritumomab tiuxetan
* Lilotomab
* Minretumomab
* Mitumomab
* Moxetumomab pasudotox†
* Naptumomab estafenatox
* Nofetumomab merpentan
* Pemtumomab†
* Pintumomab
* Racotumomab
* Satumomab pendetide
* Solitomab
* Taplitumomab paptox
* Tenatumomab
* Tositumomab
* 3F8

"-govo-" (ovarian tumor)
Abagovomab
Igovomab
Oregovomab

"-pro-" (prostate tumor)
Capromab pendetide

"-colo-" (colonic tumor)
Edrecolomab
Nacolomab tafenatox

Chimeric ("-tuxi-")|

* Amatuximab§
* Bavituximab§
* Brentuximab vedotin
* Carotuximab†
* Cetuximab
* Derlotuximab biotin§
* Dinutuximab
* Ensituximab§
* Futuximab§
* Girentuximab†
* Indatuximab ravtansine§
* Isatuximab†
* Loncastuximab tesirine
* Margetuximab†
* Rituximab#
* Siltuximab
* Ublituximab†
* IMAB362

"-mexi-" (melanoma): Ecromeximab§

Humanized ("-tuzu-")|

* Abituzumab§
* Alemtuzumab
* Bevacizumab
* Bivatuzumab mertansine§
* Brontictuzumab§
* Cantuzumab mertansine§
* Cantuzumab ravtansine§
* Cirmtuzumab
* Citatuzumab bogatox§
* Clivatuzumab tetraxetan
* Cofetuzumab pelidotin
* Dacetuzumab§
* Demcizumab§
* Dalotuzumab§
* Denintuzumab mafodotin§
* Elotuzumab
* Emactuzumab§
* Emibetuzumab§
* Enoblituzumab§
* Etaracizumab§
* Farletuzumab§
* Ficlatuzumab§
* Flotetuzumab§
* Gemtuzumab ozogamicin‡
* Imgatuzumab§
* Inotuzumab ozogamicin†
* Labetuzumab§
* Lifastuzumab vedotin§
* Lintuzumab§
* Lorvotuzumab mertansine§
* Lumretuzumab§
* Matuzumab§
* Milatuzumab§
* Nimotuzumab†
* Obinutuzumab
* Ocaratuzumab§
* Otlertuzumab§
* Onartuzumab§
* Oportuzumab monatox†
* Parsatuzumab§
* Pertuzumab
* Pinatuzumab vedotin§
* Polatuzumab vedotin†
* Rosmantuzumab
* Rovalpituzumab tesirine†
* Sacituzumab govitecan†
* Sibrotuzumab§
* Simtuzumab§
* Tacatuzumab tetraxetan§
* Tigatuzumab§
* Trastuzumab
* Tucotuzumab celmoleukin§
* Vandortuzumab vedotin§
* Vanucizumab§
* Veltuzumab§
* Vorsetuzumab mafodotin§
* CBR96-doxorubicin immunoconjugate
* PankoMab

"-gozu-" (ovarian tumor)
Sofituzumab vedotin§

Rat/mouse hybrid
("-tumaxo-")|

* Catumaxomab
* Ertumaxomab§

Chimeric + humanized
("-tuxizu-")|

* Depatuxizumab mafodotin†
* Duvortuxizumab
* Ontuxizumab§

* #WHO-EM
* ‡Withdrawn from market
* Clinical trials:
* †Phase III
* §Never to phase III

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Indium (111In) igovomab. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Indium_(111In)_igovomab&oldid=767841"
*[v]: View this template
*[t]: Discuss this template
*[e]: Edit this template